Observational studyJournal of thrombosis and thrombolysis2026
Oxidized phospholipids on plasminogen are associated with reduced platelet surface marker expression and intrinsic reactivity.
Observational study in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00457236 (Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Elevated levels of oxidized phospholipids (OxPL) on plasminogen (OxPL-PLG) are associated with reduced time to fibrinolysis and reduced risk of cardiovascular events, but their effect on platelet function is unknown. We aimed to evaluate the association of OxPL-PLG with platelet surface marker expression, intrinsic and on‑dual anti-platelet (DAPT, aspirin plus clopidogrel)) platelet reactivity and cardiovascular events. OxPL-PLG levels were measured in pre-procedure blood samples in 2040 patients undergoing coronary angiography with or without PCI. The association of OxPL-PLG to pre-procedure and 24-hour platelet surface expression of CD62P, CD41 and PAC-1 and intrinsic and on-DAPT platelet reactivity in response to collagen and adenosine diphosphate (ADP) were assessed. The relationship of OxPL-PLG to myocardial infarction(MI)-free survival over a median 7-year follow-up was assessed using multivariable Cox regression models. Elevated levels of OxPL-PLG were significantly and inversely associated with age, male sex, severity of coronary obstruction, previous MI, PCI, and CABG. OxPL-PLG was inversely associated with platelet surface expression of CD41 (p < 0.001), CD62P (p = 0.0012) and PAC-1 (p < 0.001) at baseline and with CD41 (p = 0.001) and CD62P (p = 0.020) after DAPT. A significant inverse association was present between OxPL-PLG and intrinsic platelet reactivity in response to ADP (p < 0.001) at baseline but not after DAPT. OxPL-PLG was not associated with MI-free survival. In conclusion, elevated OxPL-PLG levels are independently associated with lower-risk clinical profile, less severe coronary disease, and reduced platelet activation and reactivity prior to DAPT. These findings suggest OxPL-PLG may modulate platelet activation and reactivity and warrant further mechanistic and clinical evaluation. EXCELSIOR study (Impact of Extent of Clopidogrel-Induced Platelet Inhibition during Elective Stent Implantation on Clinical Event Rate; ClinicalTrials.gov Identifier: NCT00457236).
Indexed as
Identifiers
41525016What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.